91 results about "Molecular medicine" patented technology

The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.

The disclosure relates to metallic nanophotonic crescent structures, or “nanocrescent SERS probes,” that enhance detectable signals to facilitate molecular detections. More particularly, the nanocrescent SERS probes of the disclosure possess specialized geometries, including an edge surrounding the opening that is capable of enhancing local electromagnetic fields. Nanosystems utilizing such structures are particularly useful in the medical field for detecting rare molecular targets, biomolecular cellular imaging, and in molecular medicine.

The invention discloses a multi-mode little animal molecular image imaging device and an imaging method thereof. The device comprises an X-ray computer tomography (CT) system, a positron emission tomography (PET) system, a single photon emission computed tomography (SPECT) system, a fluorescence molecular tomography (FMT) system, a rotating rack system, a little animal bed system, a data acquisition system and a computer, various imaging systems are sampled and stored by the data acquisition system through a data line into the computer, and various imaging systems share one little animal bed system and the same inspection shaft. According to the multi-mode little animal molecular image imaging device and the imaging method, various imaging systems share one little animal bed system and the same inspection shaft, an installing fusion molecular medicine image of four modes of X-ray CT, PET, SPECT and FMT can achieve complementary advantages of different image devices, and the obtained image result is accurate and reliable.

The temperature sensitive hydro gel medicine releasing system and its preparation process belongs to the field of medicine technology. The medicine releasing system consists of carried medicine 0.1-30 wt%, temperature sensitive hydro gel 20-90 wt%, and high molecular weight polysaccharide 5-50 wt%. The medicine releasing system is prepared through a polysaccharide-temperature sensitive hydro gel compounding process, a polysaccharide-temperature sensitive hydro gel hydrophilic emulsifying process or a polysaccharide-temperature sensitive hydro gel emulsifying process. Owing to the retarding diffusion effect during solution-gel conversion, the present invention has raised medicine carrying amount, and improved medicine stability. The present invention provides simple and practical technological scheme for the controllable conveyance of biological macro molecular medicine and other treating components and the improvement of carried medicine release.

A multi-arm tree fork type polyethanediol with active terminal group is disclosed, and can be used to modify the low-molecular medicines, and protein or polypeptide medicines for improving their solubility, stability and immunogenicity, resulting in elongated half life period and raised curative effect.

The invention relates to a medicine supplying system through skin or mucous which containing polymer assembled glue beam, and which is made up of at least polymer assembled glue beam whose particle size is less than 500nm or hydrophilic or water ground substance, it includes pasting agent, soft plaster, gel agent, emulsification agent, water liquid agent, or suspending agent. The merits lie in: it uses polymer assembled glue beam technology to overcome obstacle of skin or mucous, advances the transmission and absorption of medicine through skin or mucous. The medicine supplying system is specially applied to medicine, multi-peptide, ion type medicine, polarized medicine, hydrophobic medicine, metal compound medicine and medicine with high molecular, protein, gene type biology high molecular medicine supplying.

The invention is in the field of molecular medicine and provides methods for the treatment of acute myeloid leukemia. These methods are based on the observation that microRNA-9 and microRNA-9* are involved in the pathogenesis of the disease in that the overexpression of microRNA-9 / 9* block myeloid differentiation in vitro. More in particular, microRNA-9 / 9* were found to play a role in leukemic transformation in acute myeloid leukemia.

The invention belongs to the technical field of high-molecular medicine, and particularly relates to an antitumor medicine conjugate with folic acid receptor-mediated and photoresponsive functions and a preparation method thereof. The preparation method comprises the following steps: firstly, performing amidation reaction on folic acid and amino polyethyleneglycol; then performing amidation reaction on a product obtained in the former step and 7-ethyloic-4-hydroxymethyl coumarin to obtain a polyethyleneglycol flexible chain with a folic acid receptor targeting function and a photoresponse group; finally enabling the polyethyleneglycol flexible chain to be coupled with an antitumor medicine containing amino with an ester activation method to obtain the antitumor medicine conjugate with the folic acid receptor-mediated and photoresponsive functions. The conjugate prepared by the invention can target a tumor cell through a folic acid receptor-mediated function, and enters the cell via the endocytosis to accelerate the accumulation speed of the medicine in the tumor cell; when being irradiated by ultraviolet light with a specific wavelength or near-infrared light, the conjugate is photolyzed to release original medicine, and the medicine quickly reaches the effective concentration, so that controllable 'time / space' treatment is realized; in addition, the method provides a simple and effective manner for preparing target-controllable photoresponsive high-molecular medicine conjugates.

The invention relates to the field of molecular medicine, and in particular relates to a gene chip for leukemia diagnosis and treatment. The chip contains oligonucleotide probes with sequences in SEQ ID NO:1-137. The chip has the following beneficial effects that: the actual demands in the blood system tumor diagnosis and treatment process in China are met; the gene chip is customized by screening key indicators in examination indicators in leukemia morphology, immunology, cytogenetics and molecular biology; and the multifunctional gene chip integrates early diagnosis, early warning, prevention and diagnosis and treatment of leukemia and can improve the individual diagnosis efficiency and treatment effect of leukemia, shorten the length of stay, reduce the medical expenses and improve the technical levels of the primary-level medical and health institutions.

The disclosure relates to metallic nanophotonic crescent structures, or “nanocrescent SERS probes,” that enhance detectable signals to facilitate molecular detections. More particularly, the nanocrescent SERS probes of the disclosure possess specialized geometries, including an edge surrounding the opening that is capable of enhancing local electromagnetic fields. Nanosystems utilizing such structures are particularly useful in the medical field for detecting rare molecular targets, biomolecular cellular imaging, and in molecular medicine.

The invention relates to a medicine conveying system formed by ligand polypeptide PH1 and an application thereof. The medicine conveying system comprises a ligand polypeptide PH1, a medicine carrying system and at least one active substance, wherein the polypeptide PH1 is connected on the surface of the medicine carrying system. The invention also relates to the application of the ligand polypeptide PH1 in preparing a medicine capable of specifically binding tumor-related macrophage. Discovered and proved by long-time test, the polypeptide PH1 can well target tumor-related cells, induce the differentiation of the tumor-related cells and suppress the tumor growth; the composite of PH1 polypeptide lipidosome can well target the tumor-related macrophage and can be applied to target conveying of the tumor-related macrophage of small-molecular medicines and gene medicines. The medicine conveying system has the advantages that the transretinoic acid polypeptide lipidosome can induce the differentiation of the tumor-related macrophage and suppress the tumor growth effectively, and can be applied to inhibiting proliferation of the tumor cells and the neoplasm recurrence so as to have great medical practicability.

The present invention provides a technology and a method for preparing a high-throughput exfoliated cell chip. According to the present invention, a cervix brush is adopted to collect cervix exfoliated cells of 26 cervical lesions patients and are immediately placed into a cell preservation solution, centrifugation is performed, the supernatant is removed, a cell immobilization solution is added to immobilize cell precipitate, dehydration transparency and dipping in wax are performed, a tissue chip instrument is adopted to prepare an exfoliated cell paraffin chip and an exfoliated cell paraffin block array, and paraffin slicing is performed to prepare the exfoliated cell chip; and the defect of the conventional cytology detection is overcome, and the prepared exfoliated cell chip can be used for pathological diagnosis, IHC, in situ hybridization and other molecular medicine researches.

The invention relates to the field of molecular medicine diagnosis, and particularly relates to a biomarker composition for non-small cell lung cancer, and screening and applications of the biomarker composition. The biomarker includes a lung adenocarcinoma biomarker and / or a squamous-cell carcinoma biomarker. The lung adenocarcinoma biomarker includes at least one of hsa-miR-26a-5p, hsa-miR-126-5p, hsa-miR-139-5p, hsa-miR-152-3p, hsa-miR-451a, hsa-miR-200c-3p and hsa-miR-3135b. The squamous-cell carcinoma biomarker includes at least one of hsa-miR-26a-5p, hsa-miR-126-5p, hsa-miR-139-5p, hsa-miR-151a-3p, hsa-miR-151a-5p, hsa-miR-151b, hsa-miR-152-3p, hsa-miR-550a-3p and hsa-miR-3135b. The invention also provides a biomarker screening method and applications of the biomarkers in early-stage non-small cell lung cancer diagnosis. Early-stage diagnosis and prediction of the non-small cell lung cancer are achieved, and are made rapider and more accurate. The non-small cell lung cancer can be found ahead of time, thus facilitating in-time and early treatment and increasing the survival rate.

The invention provides a technology and method for preparing high throughput needle biopsy tissue chip. The method comprises the following steps: collecting 42 residual paraffin-embedded tissue samples of needle biopsy of patients who have been diagnosed as the breast cancer patients through pathological examination on mammary gland needle biopsy tissues; taking the corresponding normal pathological HE stained sections as the guide, cutting the paraffin-embedded tissue sections (1mm to 4mm) corresponding to the cancer parts of the HE-stained sections, preparing paraffin-embedded tissue cores, preparing breast cancer needle biopsy tissue arrays by utilizing a tissue chip instrument, cutting paraffin into slices, and preparing paraffin-embedded tissue chip of breast cancer needle biopsy tissue. The prepared needle biopsy tissue chip can be applied to molecular medical research of related diseases such as immunocytochemistry, in-situ hybridization, and the like.

The invention relates to a minimalistic gene expression construct, its transfer into cells and its use for gene expression for molecular-medical applications. According to the disclosure, a DNA construct for gene expression is provided, wherein the construct is a linear and open-chained DNA double strand comprising a promoter sequence, a coding sequence and a termination signal, wherein the construct comprises at least one L-DNA nucleotide.

The invention relates to the field of molecular medicine and pharmacology. More specifically, it relates to liposomes and their use as delivery vehicle for therapeutic compounds. Provided is a liposome comprising at least one lipid bilayer enclosing an interior compartment, wherein said lipid bilayer comprises at least one synthetic pyridinium-derived amphiphile, for instance a Saint-molecule.

The invention provides a nanocomposite of DNA tetrahedron and microRNA, and belongs to the field of nucleic acid molecular medicine. The nanocomposite of the invention is composed of microRNA and a DNA tetrahedron; the DNA tetrahedron is a tetrahedral structure formed by base pairing of four DNA single strands; and the microRNA is covalently linked to a single strand of the DNA tetrahedron. The nanocomposite of the invention has strong stability and high cell entry efficiency, can be developed into various microRNA-related drugs, and has a good application prospect.

The present invention concerns the fields of molecular medicine and targeted delivery of therapeutic agents. More specifically, the present invention relates to the identification of novel peptide sequences that incorporate the amino acids Leu-Pro-Arg (LPR), and particularly D(LPR), that selectively target VEGFR-I and NRP-I expressing cells. Targeted molecules in accor-dance with the invention are useful in the treatment and detection of neovascular or angiogenic VEGF associated disorders, including but not limited to cancer, obesity, diabetes, asthma, arthritis, cirrhosis and ocular diseases.

The invention relates to the field of molecular pharmaceutics and molecular medicine, in particular to a CD4 positive cell specific gene transfer vector and application thereof. The invention providesthe CD4 positive cell specific gene transfer vector. The transfer vector is a recombinant adeno-associated virus with a heptapeptide inserted into capsid protein of the recombinant adeno-associated virus (rAAV); and the amino acid sequence of the heptapeptide is shown as any one of SED ID NO: 1-26. According to the transfer vector, after the heptapeptide is inserted into the capsid protein of therAAV, the rAAV can efficiently deliver a transgenic element to a CD4 positive cell in a targeted mode. The transfer vector can selectively transduce the CD4 positive cell, the transgenic expression level is obviously higher than that of a wild rAAV2 vector, and effective targeted gene editing can be carried out.

The invention discloses a preparing method of a diabetes early warning and / or diagnosis kit based on hsa-miR-320a, and belongs to the field of molecular medicines and diagnosis, prevention and treatment of metabolic diseases. A biological marker for diagnosis and / or early warning of diabetes comprises a sequence segment with hsa-miR-320a, and the hsa-miR-320a is shown as SEQ ID No.1. The kit for diabetes diagnosis and / or early warning comprises an agent for quantitatively detecting the biological marker. By detecting the biological marker and / or using the kit, the diabetes can be efficiently and accurately diagnosed, and corresponding diabetes early warning and risk evaluating are conducted.

The invention provides a photoresponse-nitric oxide donor molecule and derivatives and a preparing method thereof. The photoresponse-nitric oxide donor molecule of the structure shown in the formula (I) can make a sensitive response under the low radiation intensity by selecting a proper structure, a high-molecular prodrug can be further prepared, self-assembling is further conducted, a high-molecular medicine good in performance is obtained, and the toxicity is reduced compared with an existing photoresponse-nitric oxide donor molecule.

The invention relates to materia medica, molecular medicine and disease prevention fields, in particular to a gene medicine based on recombinant adeno-associated virus and tumor angiogenesis inhibiting gene. The medicine can target at lung tissue and inhibit effectively cancer metastasis and the occurrence of pulmonary metastases.

The invention provides a heteropolyacid nano-molecular medicine as well as a preparation method and an application thereof. The medicine comprises heteropolyacid or heteropolyacid salt molecules and a coating material coating the surface of heteropolyacid or the heteropolyacid salt molecules, wherein the heteropolyacid or heteropolyacid salt molecules have the structure shown in (I), (II) or (III). The heteropolyacid nano-molecular medicine can selectively interact with tumor cells and can be used as a contrast agent in magnetic resonance imaging and CT diagnosis of tumors; besides, the medicine molecules have strong oxidation-reduction quality and light sensitivity and thus can be used as medicines assisting in thermal therapy, meanwhile, the molecules have strong X-ray absorption capacity and thus can perform functions as auxiliary radiotherapy medicines, so that diagnosis and treatment of tumors can be realized simultaneously, integration of diagnosis and treatment can be realized, targeted treatment of tumors is enhanced, and the tumor treatment effect is improved.

The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.

The invention provides a neural stem cell specific gene delivery carrier and application thereof, and relates to the technical field of molecular pharmacology and molecular medicine. The delivery vector is a novel rAAV vector obtained by carrying out random gene mutation on the basis of a recombinant adeno-associated virus 9 and carrying out multiple rounds of in-vitro screening by taking neural stem cell spheres as a model. The amino acid sequence of the capsid protein of the delivery carrier is shown as SED ID NO: 1, the delivery carrier can efficiently deliver transgenic elements to neural stem cells in a targeted mode, compared with an rAAV9 carrier commonly used for transduction of a nervous system, the delivery carrier has the advantages that the transduction efficiency of the neural stem cells is remarkably improved, and the delivery carrier can be used for preparing drugs for diseases related to the nervous system.

The invention discloses application of UL16 protein in preparation of a small molecular medicine for promoting in-vitro differentiation of embryonic stem cells, and application of stem cell transplantation in treatment of nervous system degenerative diseases. According to the invention, by construction of UL16 plasmids to transfect host cells, the fact that UL16 can promote aerobic oxidation and oxidative phosphorylation of glucose and activate the cell productivity pathway so as to increase the intracellular ATP content and improve mitochondrial functions is found. Finally, by construction ofUL16 expression plasmids to transfect mouse embryonic stem cells, mitochondrial function state enhancement and energy metabolism enhancement are found, and stem cell differentiation can be promoted.Clinical treatment of cells in a differentiation defect state and cells with a low differentiation rate is realized; and the UL16 protein is used for treating related diseases or pathological and physiological processes of mitochondrial dysfunction or hypofunction of the cells.

The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled 1 and / or frizzled-2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.

The invention belongs to the technical field of biology, and relates to a composition and method for reprogramming human astrocytes into neurons or brain-like organs. The composition for efficiently reprogramming human astrocytes into neurons comprises a substance capable of realizing OCT4 overexpression, a substance knocking down a cell cycle regulation factor p53, and a small molecule drug capable of inducing human astrocytes to be reprogrammed into neurons, wherein the small molecule drug capable of inducing the human astrocytes to be reprogrammed into the neurons is selected from one or more of the following four small molecule drugs: CHIR99021, SB431542, RepSox or Y27632. Compared with the prior art, the composition and method have the following advantages: regulation and control of two genes are combined; a brand-new small molecular medicine composition capable of efficiently reprogramming human astrocytes into neurons and brain-like organs is obtained through a large amount of screening; and reliability of the system obtained through screening is verified on astrocytes differentiated from human embryonic stem cells H9 and astrocytes of para-tumor tissues of glioma patients.

The invention discloses application of a bladder urothelium carcinoma detection combined marker, and belongs to the technical field of molecular medicine. The bladder urothelium carcinoma detection combined marker comprises the following gene combinations: TERT, TP53, FGFR3, PIK3CA and ARID1A. According to the invention, it is found for the first time that a combination of five genes of TERT, TP53, FGFR3, PIK3CA and ARID1A can accurately diagnose bladder urothelial carcinoma. Compared with an original method, the method has the advantages that the five core gene detection combinations reduce the sequencing workload by 40 times, and good diagnostic performance is maintained.